Physician profile
Thomas M Deweert
NPI 1073560751
$2,635.84
in general payments reported to CMS, 2019-2025
20 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,546 · 2020: $273 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.71 |
| Education | $104.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.88 | 2019-2025 | |
| Janssen Biotech, INC. | $583.39 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $272.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.63 | 2019-2025 | Eohilia, Entyvio |
| Pfizer INC. | $123.61 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $75.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.56 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $38.73 | 2025 | Vowst, Zenpep |
| Lilly USA, LLC | $27.62 | 2025 | Zepbound |
| Ipsen Biopharmaceuticals, INC | $23.74 | 2025 | Iqirvo |
| Organon LLC | $21.93 | 2025 | Hadlima |
| Daiichi Sankyo INC. | $21.45 | 2019 | |
| Boston Scientific Corporation | $21.16 | 2019 | |
| Redhill Biopharma INC. | $20.64 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $18.69 | 2020 | |
| Shionogi INC | $18.30 | 2020 | |
| Ardelyx, INC. | $16.01 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $15.33 | 2019 | |
| Braintree Laboratories, INC. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Deweert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.